Oragenics Provides Update On ONP-002, Intended To Treat Concussion And Receives Notice Of Non-Compliance With NYSE American Listing Standards
Portfolio Pulse from Benzinga Newsdesk
Oragenics, Inc. (NYSE:OGEN) provided an update on its lead candidate, ONP-002, for treating concussions, with Phase 2 trials expected to start in Q4 2024. The company also received a notice of non-compliance with NYSE American listing standards but has an approved plan to regain compliance by October 18, 2025.
August 16, 2024 | 8:31 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Oragenics announced progress on ONP-002 for concussion treatment, with Phase 2 trials expected in Q4 2024. The company also received a non-compliance notice from NYSE but has an approved plan to regain compliance by October 2025.
The update on ONP-002 is positive for the company's long-term prospects, but the non-compliance notice from NYSE introduces short-term uncertainty. The approved compliance plan mitigates some risk, but the stock may experience volatility.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100